Avalon
Log In
Contact

Analytics

Transform Oncology Care

with Precision-Driven Genetic Testing and Drug Management

Learn More

We’re redefining the future of oncology care.

Navigating the journey from diagnosis to optimal treatment is incredibly challenging. That’s why therapy and genetic testing authorization are so important. They can significantly reduce the time it takes to find the most effective treatment. Our goal is simple: to improve health outcomes and make the process smoother and more accessible, ultimately helping to lower healthcare costs and streamline the experience.

Making oncology care faster, smarter, and more personal

Faster diagnosis-to-treatment

Reduce the standard 40–60-day gap between diagnosis and treatment to 10-15 days.

Personalized treatment

Match patients to therapies tailored to their tumor’s genetic profile.

Improved outcomes

Identify precise mutations, so patients receive the most effective treatment while avoiding harmful side effects.

Cost savings

Broad panel genetic testing and modest NGS expansion can deliver $8,500 PMPM savings and $75 per life-year gained—while improving treatment outcomes.

Standardized and streamlined

Through automation, we standardize testing protocols, reduce prior authorization delays, and ensure consistent care across patient populations.

How can Avalon transform your lab data into actionable insights?

Connect with us

Genetic testing matters more than ever.

The impact of genetic testing and targeted therapies in treating cancers like non-small cell lung cancer (NSCLC) is undeniable. However, genetic tests are still massively underutilized.

29%

of more than 27k patients with NSCLC were not on the appropriate targeted treatment based on their genetic lab results.

18%

of patients with NSCLC received all NCCN-recommended gene mutation tests.

43%

of patients with NSCLC are on a targeted drug without evidence of undergoing genetic testing.

44%

of more than 9.5k patients had a positive biomarker and were not on the therapy recommended by the National Comprehensive Cancer Network (NCCN).

21K

potential average additional life-years gained

$200

PMPM savings

$17k

potential total average cost per LYG

Proper use of NGS tests could add over 21,000 life-years gained annually while lowering treatment costs significantly.

Replacing single gene testing (SGT) at the current rate of 80% with NGS testing would result in an average additional 21,09.6 LYG and reduce cost per LYG by an average of $599. If 100% of eligible patients were tested with NGS and each identified patient had matched treatment, the total average cost per LYG would be $16,641.57.

Using average allowable amounts to reduce improper drug usage for just 10% of patients could translate to more than $200 PMPM savings.

Transformative solutions for all stakeholders.

Our innovative program ensures patients, providers, and payers receive cost-effective, life-enhancing cancer care through streamlined authorization, standardized testing protocols, and automated therapy matching. With our expertise, we are driving unparalleled efficiency, substantial cost savings, and continuous quality improvement in the management of oncology drugs.

Breaking down Barriers and Optimizing Drug Treatment for Cancer Patients

Watch the Webinar

NSCLC Diagnosis & PA Initiation

The process begins with a diagnosis. An automated prior authorization (PA) is triggered for a liquid biopsy genetic test, using Avalon’s system. This speeds the process dramatically by eliminating manual steps.

Avalon uses contracted labs that are part of a streamlined network.

This ensures that genetic testing is expedited, eliminating 10–12 days compared to traditional routing.

Avalon immediately receives test results and applies Tumor Mutation Matching Logic.

This avoids back-and-forth communication delays between labs and providers.

The provider gets a ready-to-act Approved Drug Report earlier than in typical workflows.

Automated authorizations for testing and specialty drugs streamline the process by replacing manual prior authorization submissions, significantly reducing delays in accessing necessary tests and medications.

Auditing and analytics occur throughout the process and after to ensure consistency.

The Result?

Patients experience better survival rates and optimized treatment plans with fewer side effects.

Health payors save significantly with reduced improper drug use and lower overall treatment costs.

Healthcare providers eliminate administrative hurdles and focus on delivering high-quality care.

Join us in driving change

Our proven solutions demonstrate that better outcomes are possible with more intelligent, data-driven oncology drug management systems. We combine precision, efficiency, and control to provide unparalleled support for every stakeholder.

Contact Avalon